Choto-san, a Kampo formula, improves chronic cerebral hypoperfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor.
A recent double-blind and placebo-controlled study demonstrated a beneficial effect of Choto-san, a Kampo (traditional medicine of Japan) formula, on cognitive impairment in patients with vascular dementia. However, the neuronal mechanism underlying the therapeutic effects of this formula remains to be clarified. Using a chronic cerebral hypoperfusion model, we investigated the effect of Choto-san on cognitive dysfunction in mice to clarify its mechanism of actions. Chronic cerebral hypoperfusion was induced by permanent occlusion of both the common carotid arteries (2VO). Choto-san and Uncaria, a major constituent of Choto-san, caused an improvement in 2VO-induced learning deficits, whereas Uncaria-free Choto-san did not. The effects of Choto-san and Uncaria were blocked by pirenzepine, a selective muscarinic M1 antagonist. In a tube-dominance test, 2VO induced increased rates of assertive behavior in mice. 2VO mice administered Choto-san showed significantly reduced rates of assertive behavior compared to vehicle-treated controls, whereas Uncaria-free Choto-san and Uncaria had little effect on 2VO-induced assertive behavior. 2VO caused a significant decrease in the level of acetylcholine (ACh) contents in the brain, and the daily administration of Choto-san or Uncaria raised the ACh level to that in the sham-operated controls. These results suggest that Choto-san has an ameliorating effect on the spatial memory deficit caused by chronic hypoperfusion, and that the effect is mainly attributable to Uncaria. Moreover, it was suggested that the effects of Choto-san and Uncaria are at least partly mediated by stimulation of the muscarinic M1 receptor.
Murakami
Yukihisa
Y
Division of Medicinal Pharmacology, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan.
Zhao
Qi
Q
Harada
Kousuke
K
Tohda
Michihisa
M
Watanabe
Hiroshi
H
Matsumoto
Kinzo
K
D000109:Acetylcholine / Q000378:metabolism; D000374:Aggression / Q000187:drug effects; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000150:complications; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D017536:Carotid Artery, Common / Q000473:pathology; D002540:Cerebral Cortex / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007859:Learning Disabilities / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D020835:Medicine, Kampo; D051379:Mice; D008813:Mice, Inbred ICR; D018727:Muscarinic Antagonists / Q000494:pharmacology; D008517:Phytotherapy; D010890:Pirenzepine / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D043643:Receptor, Muscarinic M1 / Q000502:physiology*; D032070:Uncaria / Q000737:chemistry
D000470:Alkaloids; D004365:Drugs, Chinese Herbal; D018727:Muscarinic Antagonists; D043643:Receptor, Muscarinic M1; C120250:choto-san; D010890:Pirenzepine; D000109:Acetylcholine